secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001654954-25-005768
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences Q1 net loss $1.0M; pivots to metabolic disease diagnostics, plans FDA de novo trial
--------------------------------------------------------------------------------

- Net loss $1.0M in Q1 2025 vs $2.8M in Q1 2024; operating expenses down 46% to $1.5M.
- Cash burn improved to $1.2M in Q1 2025 from $1.7M in Q1 2024; cash at April 30 was $2.5M after $0.8M ATM raise.
- Strategic pivot to point-of-care liver fat diagnostics for metabolic disease; redesigned TAEUS system with AI.
- Revised FDA regulatory strategy: plans prospective multicenter trial of ~250 subjects for De Novo submission.
- Two new patents issued in China, bringing IP portfolio to 84 total.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425005768/0001654954-25-005768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425005768/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-005768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer